Nuclear Factor-κB: Central Regulator in Ocular Surface Inflammation and Diseases
Nuclear Factor-κB: Central Regulator in Ocular Surface Inflammation and Diseases
复制标题
DOI：
10.1016/j.jtos.2012.04.001
复制
发表时间：
2012-07-01
期刊：
影响因子：
6.4
通讯作者：
Tong, Louis
中科院分区：
文献类型：
--
作者：
Lan, Wanwen;Petznick, Andrea;Tong, Louis
核因子-κ B（NF-kappa B）是一种重要的转录因子通路，参与了许多重要的生物学过程，如炎症、细胞凋亡、应激反应、角膜伤口愈合、血管生成和淋巴管生成。许多最近的研究已经在眼表疾病的背景下研究了NF-κ B，所述眼表疾病包括化学损伤、紫外线辐射诱导的损伤、微生物感染、过敏性眼病、干眼、翼状胬肉和角膜移植排斥。本文的目的是总结有关NF-κ B B的调节途径和NF-κ B B途径所控制的过程的关键发现。在先天防御系统中，NF-κ B参与来自toll样受体2、3、4、5和7的信号传导，这些受体在结膜、角膜缘和角膜上皮细胞中表达。这些决定了眼部对感染的反应，例如由铜绿假单胞菌、金黄色葡萄球菌、腺病毒和单纯疱疹病毒-1引起的感染。天然血管生成抑制剂增强NF-κ B B，这可能通过促分裂原活化蛋白激酶和过氧化物酶体增殖物活化受体γ发生。在碱损伤中，抑制NF-κ B B可以减少角膜血管生成，这提示了一种可能的治疗策略。还讨论了NF-κ B抑制剂在疾病中的评价，包括大黄素、贝西沙星、BOL-303242-X（mapracorat）、胸腺素-β 4、表没食子儿茶素没食子酸酯、紫苏叶提取物和IKK β靶向短干扰RNA。
The nuclear factor-kappa B (NF-kappa B) is a key transcription factor pathway that is responsible for many key biological processes, such as inflammation, apoptosis, stress response, corneal wound healing, angiogenesis, and lymphangiogenesis. Numerous recent studies have investigated NF-kappa B in the context of ocular surface disorders, including chemical injury, ultraviolet radiation-induced injury, microbial infections, allergic eye diseases, dry eye, pterygium, and corneal graft rejection. The purpose this article is to summarize key findings with regard to the pathways regulating NF-kappa B and processes governed by the NF-kappa B pathway. In the innate defense system, NF-kappa B is involved in signaling from the toll-like receptors 2, 3, 4, 5 and 7, which are expressed in conjunctival, limbal, and corneal epithelial cells. These determine the ocular responses to infections, such as those caused by Pseudomonas aeruginosa, Staphylococcus aureus, adenovirus, and herpes simplex-1 virus. Natural angiogenic inhibitors enhance NF-kappa B, and this may occur through the mitogen-activated protein kinases and peroxisome proliferator-activated receptor gamma. In alkali injury, inhibition of NF-kappa B can reduce corneal angiogenesis, suggesting a possible therapeutic strategy. The evaluation of NF-kappa B inhibitors in diseases is also discussed, including emodin, besifloxacin, BOL-303242-X (mapracorat), thymosin-beta 4, epigallocatechin gallate, Perilla frutescens leaf extract and IKK beta-targeting short interfering RNA.